NEW YORK (360Dx) – Spanish firm Zenosense said today that its UK-based joint venture MIDS Medical has engaged with Future Diagnostics Solutions for assay development services.
Through its joint venture ownership in MIDS Medical, Zenosense primarily focuses on the development and commercialization of MIDS Cardiac, a point-of-care handheld device for the early detection of cardiac event biomarkers, which is used to accelerate the triage, diagnosis, treatment, and disposition of patients reporting chest pain with suspected acute myocardial infarction.
Zenosense noted that during the current testing and development phase of its point-of-care handheld device, Future Diagnostics' consulting services will inform the MIDS Medical development team of design parameters for a future cardiac assay planned to be embodied in a test strip in a second phase of development. The collaboration is expected to assist MIDS Medical in design areas including microfluidic and magnetic detection optimization for a planned, high-sensitivity troponin assay, Zenosense said.
Ernst Lindhout, R&D director of Wijchen, Netherlands-based Future Diagnostics, noted that the MIDS technology offers the prospect of high-sensitivity, magnetic detection in an automated, POC platform, "a novel approach from current optical detection systems."
Future Diagnostics specializes in in vitro diagnostic immunoassay development, biomarker qualification, point-of-care test development, and OEM contract manufacturing. The firm provides support services related to feasibility and optimization, verification, technical transfer, and validation, and it has an FDA-registered facility that's compliant with regulatory requirements to manufacture IVD products or assays that are going to market.